Oxford Immunotec Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Dell shares surge on record AI server bookings
- 'No panic anywhere' may be the problem, BofA strategists warn
- AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
- Kroger cuts same-store sales outlook, keeps earnings guidance
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Oxford Immunotec (OXFD) Tops Q2 EPS by 6c, Revenues Beat; Offers Q3 & FY19 Revenues Above Consensus
August 6, 2019 7:49 AM EDTOxford Immunotec (NASDAQ: OXFD) reported Q2 EPS of $0.02, $0.06 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $19.6 million versus the consensus estimate of $19.39 million.
We are very pleased to be reporting another quarter of strong growth in 2019, said Dr. Peter... More
